Flip the model.
The hidden market exists. The question is which pipeline finds it first.
- Every point is a person.
- Visible to the record
- Hidden until you look
One inversion. Everything downstream of it changes.
Healthcare creates the record first.
- Data
- Patient
Symptoms drive care. Care creates the record. The record finds the patient. The model is strongest exactly where the patient is already visible, and silent everywhere else.
Therapeutic need defines the population.
- Therapeutic need
- Population
- Patient
- Data
Begin with the need. The record follows. Need defines the population. The population surfaces the patient. Data arrives last, and it is data that did not exist before.
Find the patient before sickness creates the data.
The hidden market is documented.
Diagnostic invisibility is already visible in public-health surveillance. Large, clinically relevant populations routinely exist before the record can see them.
adults with prediabetes do not know they have it.
of adults age 20+ with CKD did not know they had CKD.
of people living with chronic hepatitis B remained undiagnosed at end-2022.
of people living with hepatitis C remained undiagnosed by end-2022.
Hidden populations exist. The question is how early a pipeline can find them.
What the evidence does, and does not, establish
These surveillance estimates should not be combined into a single prevalence estimate. They establish something more fundamental: diagnostic and risk invisibility is large enough, across multiple therapeutic domains, to be a strategic problem rather than a marginal data problem.
Sources: CDC, “Prediabetes: Could It Be You?” (Feb. 17, 2026); CDC, “Chronic Kidney Disease in the United States, 2026” (Mar. 2026); WHO, “Priorities in planning hepatitis B and C testing services” (Dec. 5, 2024).
Retrospective data reconstructs history. Prospective observation is what moves identification earlier.
Condition or risk exists, but the relevant record is incomplete or absent.
The person becomes visible. Evaluation can begin.
Diagnosis, treatment and longitudinal evidence begin to accumulate.
The record shows only what has been recorded.
For a therapy with a finite commercial window, an unidentified opportunity is time-sensitive. A patient who becomes visible years later may still enter care, but the lost interval cannot be recovered. The same person may eventually appear in conventional data. Observing that person prospectively is not equivalent to discovering the history later.
Which pipeline finds it first?
Tell us who you are and why the conversation warrants the time. We reply to every request that fits.